Press Releases

Henderson, Nevada – May 18, 2022 – United Health Products, Inc. (OTCPK: UEEC), (UHP) today provided an update on its FDA regulatory process.   Regulatory Review As previously disclosed, on April 20, 2022, UHP delivered to the U.S. Food & Drug Administration (FDA) a supplemented and e-formatted Premarket Approval (PMA) response for its HemoStyp™ hemostatic […]

Henderson, Nevada – April 27, 2022 – United Health Products, Inc. (OTCPK: UEEC), (UHP) today provided an update on its FDA regulatory process and other matters.   Regulatory Review As previously disclosed in the company’s Form 10-K, the U.S. Food & Drug Administration (FDA) requested in late January 2022 that i) the responses submitted by UHP […]

Henderson, Nevada – April 1, 2022 – United Health Products, Inc. (OTCPK: UEEC), (UHP) today provided an update on its regulatory process, business condition, and other matters.   Regulatory Approvals Following the submission in October, 2021 of a response to the FDA’s questions and comments on its Premarket Approval (PMA) application, UHP and the FDA held […]

Henderson, Nevada – December 22, 2021 – United Health Products, Inc. (OTCPK: UEEC), (UHP) today provided an update on the status of its application to the Food & Drug Administration (FDA) for Pre-market Approval (PMA) of its HemoStyp™ hemostatic gauze. On December 21st, the FDA informed UHP that its review of the PMA application is ongoing […]

Henderson, Nevada – October 27, 2021 – United Health Products, Inc. (OTCPK: UEEC), (UHP) today confirmed it has submitted its response to the Food & Drug Administration’s (FDA) most recent questions and comments on the company’s Pre-market Approval (PMA) application. At this time there are no outstanding FDA information requests to UHP, however the FDA reserves […]

Henderson, Nevada – October 7, 2021 – United Health Products, Inc. (OTCPK: UEEC), (UHP), developer, manufacturer and marketer of HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today provided an update on its regulatory approval application process and other business activities. As part of its substantive review process to evaluate UHP’s PMA (Pre-market […]